Harry P Erba

19PUBLICATIONS
138CO-AUTHORS
Gene and molecular therapyQuantum optics and quantum optomechanicsHaematological tumoursMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 02, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

|Apr 08, 2026
Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Mark J Levis, Harry P Erba, Pau Montesinos

|Feb 11, 2026
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Naveen Pemmaraju, Giovanni Marconi, Pau Montesinos

|Nov 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AML.

Vivian M Liu, Megan Othus, Jasmine Naru

|Oct 06, 2025
FLT3-ITD measurable residual disease from the QuANTUM-First trial.

Mark J Levis, Harry P Erba, Pau Montesinos

|Sep 25, 2025
Ziftomenib in Relapsed or Refractory <i>NPM1</i>-Mutated AML.

Eunice S Wang, Pau Montesinos, James Foran

Pageof 4

Frequent Collaborators

10 joint publications

Mark R Litzow

5 joint publications

Anjali S Advani

4 joint publications

Richard F Little

4 joint publications

Paul M Barr